Radiosensitization by a novel Bcl-2 and Bcl-XL inhibitor S44563 in small-cell lung cancer

Yohann Loriot(Institut Gustave Roussy), Éric Deutsch(Inserm)

Cell Death and Disease

September 18, 2014

10.1038/cddis.2014.365

Cited by 45

Related Papers

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

|Science|2017|5.4k

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|3.7k

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

|New England Journal of Medicine|2014|3k

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

|Nature|2014|2.4k

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

|The Lancet|2016|2.2k